L.E.A.P.S. heteroconjugate is able to prevent and treat experimental autoimmune myocarditis by altering trafficking of autoaggressive cells to the heart

Daniela Cihakova, Jobert G. Barin, G. Christian Baldeviano, Miho Kimura, Monica V. Talor, Daniel H. Zimmerman, Eyal Talor, Noel R. Rose

Research output: Contribution to journalArticle

Abstract

We evaluated the efficacy of the Ligand Epitope Antigen Presentation System (L.E.A.P.S.™) in preventing or treating experimental autoimmune myocarditis (EAM) in A/J mice. L.E.A.P.S. (here, J-My-1) is a conjugate of the myocarditogenic peptide of cardiac myosin MyHCα334-352 (My-1) and J peptide, derived from the sequence of human β-2 microglobulin. Remarkably, early prophylactic (J-My-1 injected on days - 14 and - 7 before EAM induction), late prophylactic (J-My-1 injected on days 0, 7, 14, and 21), and therapeutic (J-My-1 injected on days 7, 14, and 21 or 10, 17 and 24) administration of J-My-1 significantly decreased the incidence and severity of EAM. However, extended therapeutic treatment was associated with anaphylaxis and death, corresponding with global immune activation associated with J-My-1 treatment. In J-My1-treated animals, we observed expanded numbers of activated CD69+ and CD44+ CD4+ and CD8+ T cells in the spleens. J-My-1 treatment also increased the proportion of CD11c+ dendritic cells in spleens and induced strong production of anti-J-My-1 specific antibodies. J-My-1 injections resulted in decreased levels of chemokines MIP-1α and IP-10 in hearts. We propose that J-My-1 treatment interferes with trafficking of autoaggressive immune cells to the heart.

Original languageEnglish (US)
Pages (from-to)624-633
Number of pages10
JournalInternational Immunopharmacology
Volume8
Issue number5
DOIs
StatePublished - May 2008

Fingerprint

Myocarditis
Antigen Presentation
Epitopes
Ligands
Therapeutics
Spleen
Cardiac Myosins
Peptides
Anaphylaxis
Chemokines
Dendritic Cells
T-Lymphocytes
Injections
Antibodies
Incidence

Keywords

  • Altered peptide ligand (APL)
  • Antigen-specific therapy
  • Autoimmunity
  • Experimental autoimmune myocarditis (EAM)
  • Myocarditis

ASJC Scopus subject areas

  • Immunology
  • Pharmacology

Cite this

L.E.A.P.S. heteroconjugate is able to prevent and treat experimental autoimmune myocarditis by altering trafficking of autoaggressive cells to the heart. / Cihakova, Daniela; Barin, Jobert G.; Baldeviano, G. Christian; Kimura, Miho; Talor, Monica V.; Zimmerman, Daniel H.; Talor, Eyal; Rose, Noel R.

In: International Immunopharmacology, Vol. 8, No. 5, 05.2008, p. 624-633.

Research output: Contribution to journalArticle

Cihakova, Daniela ; Barin, Jobert G. ; Baldeviano, G. Christian ; Kimura, Miho ; Talor, Monica V. ; Zimmerman, Daniel H. ; Talor, Eyal ; Rose, Noel R. / L.E.A.P.S. heteroconjugate is able to prevent and treat experimental autoimmune myocarditis by altering trafficking of autoaggressive cells to the heart. In: International Immunopharmacology. 2008 ; Vol. 8, No. 5. pp. 624-633.
@article{d9dcc01b46474822aca8ebda497c0787,
title = "L.E.A.P.S. heteroconjugate is able to prevent and treat experimental autoimmune myocarditis by altering trafficking of autoaggressive cells to the heart",
abstract = "We evaluated the efficacy of the Ligand Epitope Antigen Presentation System (L.E.A.P.S.™) in preventing or treating experimental autoimmune myocarditis (EAM) in A/J mice. L.E.A.P.S. (here, J-My-1) is a conjugate of the myocarditogenic peptide of cardiac myosin MyHCα334-352 (My-1) and J peptide, derived from the sequence of human β-2 microglobulin. Remarkably, early prophylactic (J-My-1 injected on days - 14 and - 7 before EAM induction), late prophylactic (J-My-1 injected on days 0, 7, 14, and 21), and therapeutic (J-My-1 injected on days 7, 14, and 21 or 10, 17 and 24) administration of J-My-1 significantly decreased the incidence and severity of EAM. However, extended therapeutic treatment was associated with anaphylaxis and death, corresponding with global immune activation associated with J-My-1 treatment. In J-My1-treated animals, we observed expanded numbers of activated CD69+ and CD44+ CD4+ and CD8+ T cells in the spleens. J-My-1 treatment also increased the proportion of CD11c+ dendritic cells in spleens and induced strong production of anti-J-My-1 specific antibodies. J-My-1 injections resulted in decreased levels of chemokines MIP-1α and IP-10 in hearts. We propose that J-My-1 treatment interferes with trafficking of autoaggressive immune cells to the heart.",
keywords = "Altered peptide ligand (APL), Antigen-specific therapy, Autoimmunity, Experimental autoimmune myocarditis (EAM), Myocarditis",
author = "Daniela Cihakova and Barin, {Jobert G.} and Baldeviano, {G. Christian} and Miho Kimura and Talor, {Monica V.} and Zimmerman, {Daniel H.} and Eyal Talor and Rose, {Noel R.}",
year = "2008",
month = "5",
doi = "10.1016/j.intimp.2008.01.004",
language = "English (US)",
volume = "8",
pages = "624--633",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - L.E.A.P.S. heteroconjugate is able to prevent and treat experimental autoimmune myocarditis by altering trafficking of autoaggressive cells to the heart

AU - Cihakova, Daniela

AU - Barin, Jobert G.

AU - Baldeviano, G. Christian

AU - Kimura, Miho

AU - Talor, Monica V.

AU - Zimmerman, Daniel H.

AU - Talor, Eyal

AU - Rose, Noel R.

PY - 2008/5

Y1 - 2008/5

N2 - We evaluated the efficacy of the Ligand Epitope Antigen Presentation System (L.E.A.P.S.™) in preventing or treating experimental autoimmune myocarditis (EAM) in A/J mice. L.E.A.P.S. (here, J-My-1) is a conjugate of the myocarditogenic peptide of cardiac myosin MyHCα334-352 (My-1) and J peptide, derived from the sequence of human β-2 microglobulin. Remarkably, early prophylactic (J-My-1 injected on days - 14 and - 7 before EAM induction), late prophylactic (J-My-1 injected on days 0, 7, 14, and 21), and therapeutic (J-My-1 injected on days 7, 14, and 21 or 10, 17 and 24) administration of J-My-1 significantly decreased the incidence and severity of EAM. However, extended therapeutic treatment was associated with anaphylaxis and death, corresponding with global immune activation associated with J-My-1 treatment. In J-My1-treated animals, we observed expanded numbers of activated CD69+ and CD44+ CD4+ and CD8+ T cells in the spleens. J-My-1 treatment also increased the proportion of CD11c+ dendritic cells in spleens and induced strong production of anti-J-My-1 specific antibodies. J-My-1 injections resulted in decreased levels of chemokines MIP-1α and IP-10 in hearts. We propose that J-My-1 treatment interferes with trafficking of autoaggressive immune cells to the heart.

AB - We evaluated the efficacy of the Ligand Epitope Antigen Presentation System (L.E.A.P.S.™) in preventing or treating experimental autoimmune myocarditis (EAM) in A/J mice. L.E.A.P.S. (here, J-My-1) is a conjugate of the myocarditogenic peptide of cardiac myosin MyHCα334-352 (My-1) and J peptide, derived from the sequence of human β-2 microglobulin. Remarkably, early prophylactic (J-My-1 injected on days - 14 and - 7 before EAM induction), late prophylactic (J-My-1 injected on days 0, 7, 14, and 21), and therapeutic (J-My-1 injected on days 7, 14, and 21 or 10, 17 and 24) administration of J-My-1 significantly decreased the incidence and severity of EAM. However, extended therapeutic treatment was associated with anaphylaxis and death, corresponding with global immune activation associated with J-My-1 treatment. In J-My1-treated animals, we observed expanded numbers of activated CD69+ and CD44+ CD4+ and CD8+ T cells in the spleens. J-My-1 treatment also increased the proportion of CD11c+ dendritic cells in spleens and induced strong production of anti-J-My-1 specific antibodies. J-My-1 injections resulted in decreased levels of chemokines MIP-1α and IP-10 in hearts. We propose that J-My-1 treatment interferes with trafficking of autoaggressive immune cells to the heart.

KW - Altered peptide ligand (APL)

KW - Antigen-specific therapy

KW - Autoimmunity

KW - Experimental autoimmune myocarditis (EAM)

KW - Myocarditis

UR - http://www.scopus.com/inward/record.url?scp=41149180875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41149180875&partnerID=8YFLogxK

U2 - 10.1016/j.intimp.2008.01.004

DO - 10.1016/j.intimp.2008.01.004

M3 - Article

C2 - 18387504

AN - SCOPUS:41149180875

VL - 8

SP - 624

EP - 633

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 5

ER -